All Things CLL With Nitin Jain
Healthcare Unfiltered
00:00
Ibrutinib vs. Akhala Obin: A Comparison
The data we have with NTC2 and antibody which is really with Akhala butinib so we have with Ibrutinib also there was a study done with the retuximab there was no benefit. When they did Akhala Obin versus Akhala at five-year time point there was about 12 percentage point PFS improvement for Akhala patients. If you're really going to use Obin why not just do veneetal claxo-mutuzumab right? That's a tiny bit of approach for my patients right rather than just doing this and then still continuing Akhala forever.
Transcript
Play full episode
